Morning Movers: Bausch + Lomb surges as said to consider potential sale

Check out this morning’s top movers from around Wall Street, compiled by The Fly. 

HIGHER –

• NuCana (NCNA) up 149% after presenting final data from the Phase 2 NuTide:701 study at ESMO
• Zentalis (ZNTL) up 40% after the FDA lifted the partial clinical hold on studies of azenosertib
• Bausch + Lomb (BLCO) up 17% after Financial Times reported Bausch + Lomb is considering a sale as a strategy to disentangle itself from its parent company
• Nuvalent (NUVL) up 21% after the company provided development updates for zidesamtinib and NVL-655
• Ascendis Pharma (ASND) up 18% after announcing topline data from the pivotal double-blind placebo-controlled ApproaCH Trial of TransCon CNP

UP AFTER EARNINGS –

• ModivCare (MODV) up 2%

DOWN AFTER EARNINGS –

• AstroNova (ALOT) down 2%

LOWER –

• iTeos Therapeutics (ITOS) down 13% after reporting follow-up interim data from GALAXIES Lung-201
• Upstart (UPST) down 8% after announcing offering of $300M of Convertible Senior Notes due 2029
• Apple (AAPL) down 2% after analyst Ming Chi-Kuo noted Apple is seeing less demand for iPhone 16 Pro and iPhone 16 Pro Max than expected